
In the final portion of our discussion with Kimberly Kue-Tsemo, PharmD, she explores the key developments that could be the most significant push toward reducing pharmacy deserts.
New drugs pending for prostate cancer: sipuleucel-T; DCVax-Prostate; satraplatin






